Educating and Advocating on behalf of those affected by myelofibrosis,
polycythemia vera, and essential thrombocythemia
| |
The Importance of MPN Clinical Trial Updates | |
|
MPN Advocacy and Education International has played an integral role in new drug development for MPN’s in many ways. One very important role we play is getting the information out to the MPN Community about all the trials underway. Patients and physicians benefit from this information in several ways. Patients who are aware of trials may meet the criteria to participate and will bring the information to their hematologists. Physicians who are not MPN experts, review the information and often will reach out to us or attend our webinars and watch the recordings to learn more.
We have assisted many MPN specialists in ramping up their institutional clinical trials which have often resulted in findings that are critical to the future treatments and care of MPN patients. The Industry Partners who share their updates also have drugs in the pipeline that are showing great promise. We now have four treatment options for MPN patients and that would not have happened without clinical trials.
We greatly appreciate all of those who have participated in trials and are currently in trials. We would be nowhere without you!
| |
Clinical Trial Updates for Patients
Wednesday, May 8, 2024
11:00am-12:30pm EST
| |
Clinical Trial Updates for Physicians
Thursday, May 9, 2024
11:00am-12:30pm EST
| |
A Grand Time in Grand Rapids | |
|
MPN Advocacy & Education International held an in-person patient/caregiver event in Grand Rapids, Michigan on April 25th. The room buzzed with excitement and camaraderie as patients and caregivers had the opportunity to engage with each other and MPN experts on a wide range of topics.
Dr. Anas Al-Janadi gave an overview of the history of MPNs and defined where we are in our current understanding of the disease and what the future may hold. While exciting discoveries were made that supported the development of drug therapies for MPN patients; such as the JAK2 mutation in 2005 and later the MPL and CALR mutations, the MPN community is still working to better understand the reasons for disease progression and ways to reduce symptom burden. Read more
| |
Do your allele burden levels correlate to your risk of progression? | |
|
Dr. Prithviraj Bose, MD Anderson Cancer Center, answers patient's questions about the impact of allele burden on disease prognosis and progression.
Click on the video above to watch
| |
News from MPN Specialists | |
|
Dr. Sekeres on the Rationale for the FDA Approval of Momelotinib in Myelofibrosis
Mikkael A. Sekeres, MD, MS, professor, medicine, chief, Division of Hematology, Leukemia Section, the University of Miami Health System, Sylvester Comprehensive Cancer Center, discusses the background on the FDA approval of momelotinib (Ojjaara) for the treatment of patients with anemic myelofibrosis.
Learn more
| |
|
Dr. Mikkael Sekeres
University of Miami Health
| |
|
Dr. Masarova on the Latest Updates Across Myeloproliferative Neoplasms
Lucia Masarova, MD, PhD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses some of the latest updates across myeloproliferative neoplasms (MPNs). She discusses some significant studies, including the TRANSFORM-1 and MANIFEST-2 studies (NCT04472598; NCT04603495), and emerging therapeutic approaches, like combining ruxolitinib (Jakafi) with other agents, such as pelabresib (CPI-0610) and navitoclax.
Learn more
| |
|
Dr. Lucia Masarova
MD Anderson Cancer Center
| |
|
Dr. Guo Develops Test Promising Answers for Cancer Patients
Cancer researcher, Belinda Guo, knows that one of the biggest issues for people with myeloproliferative neoplasms (a group of rare blood cancers), is not knowing if the cancer will progress.
Dr Belinda Guo and her team at the University of Western Australia’s Translational Cancer Pathology Laboratory have invented a new blood-based test that detects specific changes in the blood of patients diagnosed with myelofibrosis.
Learn more
| |
|
Dr. Belinda Guo
University of Western Australia
| |
|
August 22, 2024
Asheville, North Carolina
The Omni Grove Park Inn
| |
|
September 27, 2024
10th Annual Women's Conference
New York
Park Hyatt New York
Additional details and registration will be available soon
| | |
|
Each month throughout the summer, Justin Grinnell, a certified strength and conditioning specialist, and Natalie Giocondo, a certified yoga and meditation instructor, will host one hour of exercise training for MPN patients and yoga and mindfulness practices.
| |
MPN Advocacy & Education Int'l | Website
| |
|
MPN Advocacy & Education International would not be able to provide our educational programs, webinars and many other MPN resources without the assistance of our Industry Partners.
We are grateful for their support.
| | | | |
